La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Apogee Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Apogee Therapeutics..

Apogee Therapeutics (NASDAQ:APGE) Azioni, Catena delle Opzioni

APOGEE THERAPEUTICS INC

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics Inc

Morgan Stanley analyst Dara Mohsenian maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $104 to $96.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $96

Building America's Future, a political action committee (PAC) backed by&nbsp;Elon Musk, has allocated over a million dollars for the promotion of recent White House victories, including a GOP policy package that Musk had previously criticized.
The PAC is set to launch a 30-second ad titled &#8220;Independence&#8221; on Fox News. The ad commends President Trump and the GOP for the passage of the &#8220;One Big, Beautiful Bill,&#8221; which extends Trump&#8217;s 2017 tax cuts and other GOP victories, despite nearly $1 trillion in impending Medicaid cuts, &nbsp;<a href="https://www.politico.com/news/2025/08/04/super-pac-spends-promote-megabill-00491486?ref=biztoc.com">reported</a>&nbsp;Politico.
The ad, which will debut on Monday, lauds the tax cuts for working families, including the doubling of the child tax credit and tax reductions for seniors. This is despite Musk&#8217;s previous denunciation of the megabill as &#8220;utterly insane and destructive.&#8221;
Despite Musk&#8217;s opposition, the PAC has chosen to support the megabill.&nbsp;Generra Peck, a senior advisor to the PAC, praised President Trump, Leader&nbsp;John Thune, and Speaker&nbsp;Mike Johnson&nbsp;for their &#8220;tremendous strength and vision&#8221; in getting the&nbsp;historic tax cuts for working&nbsp;families passed.
<h2 class="wp-block-heading">Musk Donates $15 Million To Trump&#8217;s MAGA And GOP Despite His Sharp Criticisms</h2>
Musk&#8217;s support for the GOP and Trump&#8217;s policies has been a subject of interest. Just days before he called for the formation of a third party, Musk&nbsp;<a href="https://www.benzinga.com/news/politics/25/08/46784703/elon-musk-donated-15-million-to-trumps-maga-and-gop-just-3-days-before-his-third-party-bid">donated $15 million</a>&nbsp;to President Trump&#8217;s MAGA Inc. and the Republican Party. This move raised questions about Musk&#8217;s political intentions and his potential role in shaping the future of the GOP.
Moreover, Musk has publicly criticized Trump&#8217;s policies, particularly those related to renewable energy subsidies. In July, Musk slammed Trump for axing subsidies on renewable energy. Musk stated that SpaceX secured all <a href="https://www.benzinga.com/markets/tech/25/07/46623210/elon-musk-slams-trump-for-axing-subsidies-on-renewable-energy-says-spacex-won-nasa-contracts-by-doing-a-better-job-for-less-money">NASA contracts </a>by &#8220;doing a better job for less money.&#8221; He warned that awarding those contracts to other companies could double costs for taxpayers and risk leaving astronauts stranded in space.
<h2 class="wp-block-heading">Trump Turns to Altman, Amazon Amid Musk Fallout</h2>
Musk&#8217;s strained relationship with Trump has led to Sam Altman, CEO of OpenAI, <a href="https://www.benzinga.com/news/politics/25/07/46508730/heres-how-sam-altman-quietly-replaced-elon-musk-as-donald-trumps-go-to-ai-advisor">replacing Musk </a>as Trump's go-to AI advisor. Also, the Trump administration is reportedly considering alternative partners for the Golden Dome missile defense system, including Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper.
READ MORE: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/08/46817700/ex-trump-lawyer-says-trump-could-set-sights-on-musks-billions-it-bothers-him-that-he-is-the-richest-man">Ex-Trump Lawyer Says Trump Could Set Sights on Musk&#8217;s Billions: &#8216;It Bothers Him That He Is the Richest Man&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AMZN

Elon Musk-Backed PAC Spends Millions On Pro-Trump Ad Campaign Lauding 'Big, Beautiful Bill:' Report

Barclays analyst Julian Mitchell maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Equal-Weight and raises the price target from $240 to $243.

Barclays Maintains Equal-Weight on Illinois Tool Works, Raises Price Target to $243

Keybanc analyst Aleksey Yefremov maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $93 to $79.

Keybanc Maintains Overweight on Eastman Chemical, Lowers Price Target to $79

Morgan Stanley analyst Meta Marshall maintains Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) with a Equal-Weight and raises the price target from $92 to $97.

COHR

Morgan Stanley Maintains Equal-Weight on Coherent, Raises Price Target to $97

American defense manufacturers are reportedly grappling with China&#8217;s decision to limit the supply of critical minerals. This move has resulted in production delays and a global scramble for mineral stockpiles.
<h2 class="wp-block-heading">Defense Firms Struggle As China Tightens Mineral Grip</h2>
Amid rising U.S.-China trade tensions, China tightened its export controls on rare earths earlier this year. Despite easing these restrictions following trade concessions from the Trump administration in June, China continues to control&nbsp;critical minerals for defense purposes, <a href="https://www.wsj.com/world/asia/china-western-defense-industry-critical-minerals-3971ec51?mod=hp_lead_pos1">reported</a> The Wall Street Journal.
China&#8217;s dominance in the global production of many critical minerals, including supplying about 90% of the world&#8217;s rare earths, has significant implications. Leonardo DRS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>), for instance, had to postpone orders by two months while seeking&nbsp;non-Chinese magnet sources,&nbsp;which are made from rare earths.
The restrictions have led to a sharp increase in the prices of materials required by the defense industry. One company was quoted a price for samarium, a crucial element for making jet-fighter engine magnets, at 60 times the standard rate. This has resulted in&nbsp;the cost of defense systems&nbsp;skyrocketing, according to suppliers and defense executives. 
<h2 class="wp-block-heading">AI, Drones Drive Urgency In Rare Earth Supply Effort</h2>
The U.S. has been grappling with a <a href="https://www.benzinga.com/markets/equities/25/07/46214341/china-showed-its-death-grip-on-rare-earths-during-trump-tariff-war-but-craig-shapiro-says-this-2-billion-plan-will-secure-us-supply-heres-how">critical vulnerability </a>in its supply chain concerning rare earth supply amid rising tensions and<a href="https://www.benzinga.com/markets/equities/25/07/46214341/china-showed-its-death-grip-on-rare-earths-during-trump-tariff-war-but-craig-shapiro-says-this-2-billion-plan-will-secure-us-supply-heres-how"> ongoing trade</a> talks.&nbsp;
Defense contractors depend on Chinese-sourced minerals for microelectronics, drone motors, night-vision goggles, missile-targeting systems, and defense satellites.
Furthermore, the Defense Secretary Pete Hegseth&#8216;s move to fast-track drone manufacturing and <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46356963/drone-stocks-fly-as-defense-secretary-fast-tracks-drone-production-deployment">deployment</a> has added to the urgency of securing a stable supply of rare earths.
In a recent development, MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) CEO James Litinsky highlighted the critical role of rare earth magnets in powering the AI industry and how the U.S. can secure its position in the <a href="https://www.benzinga.com/markets/tech/25/07/46654958/mp-materials-ceo-james-litinsky-says-us-can-beat-china-in-ai-hardware-race-backed-by-400-million-pentagon-deal-to-secure-rare-earth-supply-chain">global AI race</a>. This comes on the heels of its $400 million Pentagon deal to secure the rare earth supply chain. 
On its recent earnings call, Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) CEO James Taiclet hailed the MP Materials deal as groundbreaking for securing magnet supplies for F-35 jets and cruise missiles, but noted that establishing new supply chains will take time.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46782374/palantir-lands-10-billion-army-deal-to-unify-75-contracts-into-one-ai-powered-defense-software-framework">Palantir Lands $10 Billion Army Deal To Unify 75 Contracts Into One AI-Powered Defense Software Framework</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US Defense Firms Face Tough Times As China's Mineral Curbs Trigger Global Scramble For Critical Supplies: Report

Barclays analyst David Strauss maintains Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) with a Equal-Weight and raises the price target from $235 to $295.

Barclays Maintains Equal-Weight on Huntington Ingalls Indus, Raises Price Target to $295

WIIM

ALNY

Alnylam Pharmaceuticals shares are trading higher after Wolfe Research upgraded the stock from Underperform to Peer Perform. Also, Oppenheimer upgraded the stock from Perform to Outperform and announced a $490 price target.

Morgan Stanley analyst Ricky Goldwasser maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Equal-Weight and lowers the price target from $33 to $28.

Morgan Stanley Maintains Equal-Weight on Centene, Lowers Price Target to $28

Trading Ideas

VERB

Verb Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 90.8%

GYRO

Trading Halt: Halted at 10:33:48 a.m. ET - Trading Halt: Halt News Pending

JMP Securities analyst Patrick Walravens reiterates ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Market Outperform and maintains $1300 price target.

Reiteration

JMP Securities Reiterates Market Outperform on ServiceNow, Maintains $1300 Price Target

Barclays analyst David Strauss maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Overweight and raises the price target from $140 to $190.

Barclays Maintains Overweight on Howmet Aerospace, Raises Price Target to $190

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus loss of $2.42 per share</a>.
The COVID-19 vaccine maker reported sales of $295.69 million (260.8 million euros), compared to 128.7 million euros a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/08/g46822901/biontech-announces-second-quarter-2025-financial-results-and-corporate-update" rel="noreferrer noopener">the consensus of $147.90 million</a>.
The sales increase was mainly driven by higher revenues from BioNTech&#8217;s COVID-19 vaccine collaboration.
R&amp;D expenses were 509.1&nbsp;million euros compared to 584.6&nbsp;million a year ago, mainly driven by the reprioritization of clinical trials towards focus programs.
SG&amp;A expenses decreased to 137.4 million euros, compared to 183.8 million euros a year ago, primarily due to a reduction in external services.
Cash and cash equivalents, plus security investments, totaled 15.99 billion euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/08/46791309/modernas-key-patent-win-overshadowed-by-gloomy-outlook" rel="noreferrer noopener">Moderna&#8217;s Key Patent Win Overshadowed By Gloomy Outlook</a>
<h2 class="wp-block-heading">Guidance For 2025</h2>
BioNTech <a target="_blank" href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" rel="noreferrer noopener">reaffirmed its fiscal year 2025</a> guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion euros and revenue phasing primarily concentrated in the last three to four months.
&#8220;In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy,&#8221; said Ugur Sahin, CEO and Co-Founder of BioNTech, in a statement Monday.
In June, BioNTech and&nbsp;Bristol Myers Squibb&nbsp;&amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered a co-development <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" rel="noreferrer noopener">and co-commercialization agreement</a>.
The pact focuses on BioNTech's investigational bispecific antibody, BNT327, across various solid tumor types.
&#8220;With the strategic BMS collaboration, we will further strengthen our topline and cash position. As such, we will receive an upfront cash payment of $1.5 billion in Q3 that we anticipate to be recognized as revenue over the development phase of BNT327,&#8221; said Ramón Zapata, CFO at BioNTech.
In June, BioNTech agreed to acquire CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) in an all-stock transaction. With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational <a target="_blank" href="https://www.benzinga.com/m-a/25/06/45907865/biontech-mrna-cancer-portfolio-curevac-all-stock-deal" rel="noreferrer noopener">mRNA-based cancer immunotherapy</a>.
Last week, the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for BioNTech and its partner Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) LP.8.1-adapted monovalent COVID-19 <a href="https://www.benzinga.com/pressreleases/25/07/b46623604/pfizer-and-biontech-receive-positive-chmp-opinion-for-lp-8-1-adapted-covid-19-vaccine-in-the-europ" target="_blank" rel="noreferrer noopener">vaccine (COMIRNATY LP.8.1)</a>.
Price Action: BNTX stock is up 4.99% at $112.70 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/08/46826230/blade-exits-air-taxi-space-sells-unit-to-joby-to-focus-on-medical-logistics" target="_blank" rel="noreferrer noopener">Blade Exits Air Taxi Space, Sells Unit To Joby To Focus On Medical Logistics</a></li>
</ul>
Photo: Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

BNTX

CVAC

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Barclays analyst Julian Mitchell maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Overweight and raises the price target from $26 to $28.

GTES

Barclays Maintains Overweight on Gates Industrial Corp, Raises Price Target to $28

Morgan Stanley analyst Tejas Savant maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Equal-Weight and lowers the price target from $15 to $12.

AVTR

Morgan Stanley Maintains Equal-Weight on Avantor, Lowers Price Target to $12

Barclays analyst Benjamin Budish maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and raises the price target from $20 to $23.

Barclays Maintains Underweight on Franklin Resources, Raises Price Target to $23

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.65%. Currently, Cencora has a market capitalization of $55.89 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $6,020.10 today based on a price of $288.35 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754317822_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<h2 class="wp-block-heading">Introduction</h2>
Stock trading has historically been a domain dominated by institutional investors with access to proprietary tools, advanced algorithms, and teams of quantitative analysts. But the landscape is changing rapidly. Thanks to Artificial Intelligence (AI), retail investors now have access to similar advantages once reserved for Wall Street insiders. From pattern recognition to real-time sentiment analysis and personalized portfolio management, AI is rewriting the rulebook of investing.
In this article, we'll explore how AI is democratizing access to stock trading intelligence, what tools are reshaping investment decisions, and how retail traders can leverage this evolving tech landscape. We'll also look at how partnering with the right AI development company in USA or mobile app development company can offer long-term value in building intelligent investing platforms.
<h3 class="wp-block-heading">The Old Way: Limitations for Retail Investors</h3>
Until recently, most retail investors operated at a disadvantage. They relied on:
<ul class="wp-block-list">
<li>Delayed news reports</li>
<li>Outdated technical indicators</li>
<li>Human intuition</li>
<li>Manual portfolio balancing</li>
</ul>
The result? Slower reaction times, less diversification, and more emotionally-driven decisions. In contrast, hedge funds and institutional investors used machine learning models to make high-frequency trades, detect micro-trends, and exploit inefficiencies in milliseconds.
<h3 class="wp-block-heading">The AI Revolution in Retail Trading</h3>
AI is now leveling the playing field. Here's how:
<h4 class="wp-block-heading">1. Algorithmic Trading for the Masses</h4>
AI-powered trading bots were once exclusive to hedge funds. Today, platforms like Alpaca, Trade Ideas, and QuantConnect enable retail investors to use or even customize trading bots based on AI-driven rules. These bots can:
<ul class="wp-block-list">
<li>Execute trades automatically</li>
<li>Respond to market triggers in real time</li>
<li>Learn and improve over time</li>
</ul>
<h4 class="wp-block-heading">2. Sentiment Analysis from News &amp; Social Media</h4>
AI algorithms analyze millions of data points from news sources, Reddit threads, X (formerly Twitter), and financial blogs. They can measure sentiment, highlight trending tickers, and even forecast volatility spikes. Tools like Accern and StockSnips make this accessible to everyday traders.
<h4 class="wp-block-heading">3. Pattern Recognition and Predictive Analytics</h4>
Machine learning models can identify complex patterns that human traders miss. For example:
<ul class="wp-block-list">
<li>Recognizing cup-and-handle or head-and-shoulders formations</li>
<li>Predicting future price movement based on past behavior</li>
</ul>
Some trading platforms now integrate predictive analytics dashboards tailored for non-technical users.
<h4 class="wp-block-heading">4. Personalized Portfolio Management</h4>
AI-powered robo-advisors like Wealthfront and Betterment use algorithms to:
<ul class="wp-block-list">
<li>Optimize portfolios for risk tolerance</li>
<li>Rebalance investments automatically</li>
<li>Minimize tax liability</li>
</ul>
Retail investors benefit from data-backed advice without paying hefty fees to human advisors.
<h3 class="wp-block-heading">Mobile Trading Apps Powered by AI</h3>
Retail investors increasingly manage their trades through smartphones. Mobile-first platforms now embed AI in:
<ul class="wp-block-list">
<li>Trade recommendations</li>
<li>Risk alerts</li>
<li>Personalized learning modules</li>
<li>Chatbot-based investment guidance</li>
</ul>
A solid mobile app development company can integrate these AI features into intuitive, user-friendly apps that offer real-time data and frictionless execution.
For startups entering the fintech space, collaboration with an AI development company in USA ensures access to state-of-the-art NLP, predictive analytics, and secure deployment strategies.
<h3 class="wp-block-heading">Case Study: Robinhood &amp; AI-Based Recommendations</h3>
Robinhood revolutionized mobile trading, but its early approach was basic. Newer updates include:
<ul class="wp-block-list">
<li>AI-based notification systems</li>
<li>Portfolio insights based on comparative analytics</li>
<li>Behavior-driven nudges for risk-aware trading</li>
</ul>
While not perfect, these developments highlight how AI is core to retaining users and increasing lifetime value.
<h3 class="wp-block-heading">The Rise of DIY Quant Trading</h3>
Previously, quantitative trading was gatekept by PhDs and institutional quant desks. No longer.
Retail investors now have access to platforms that let them:
<ul class="wp-block-list">
<li>Backtest trading strategies using historical data</li>
<li>Use drag-and-drop AI modeling tools</li>
<li>Build bots with minimal coding knowledge</li>
</ul>
Platforms like Tradestation and TuringTrader are bringing DIY quant trading mainstream.
<h3 class="wp-block-heading">Limitations and Risks</h3>
AI is powerful, but it's not foolproof. Retail investors should remain aware of:
<ul class="wp-block-list">
<li>Overfitting models to historical data</li>
<li>Black box algorithms with limited explainability</li>
<li>Data privacy concerns</li>
<li>High reliance on third-party AI infrastructure</li>
</ul>
It's essential to treat AI as an assistant—not a magic solution.
<h3 class="wp-block-heading">Future Trends to Watch</h3>
<ol start="1" class="wp-block-list">
<li>Explainable AI in Finance: More platforms will provide transparency behind model decisions.</li>
<li>Real-Time Customization: AI will adapt portfolios dynamically based on life events or market news.</li>
<li>Voice-Driven Trading Assistants: Think Siri or Alexa for investments.</li>
<li>AI Regulation: Expect frameworks around the ethical use of AI in retail finance.</li>
</ol>
<h3 class="wp-block-heading">Building the Next AI-Driven Investment App</h3>
If you&#8217;re building a new platform for retail investing, integrating AI isn't optional—it's expected. Success depends on:
<ul class="wp-block-list">
<li>Solid UX/UI to make insights actionable</li>
<li>Secure data pipelines to ensure compliance</li>
<li>Real-time architecture to deliver latency-free execution</li>
</ul>
This is where partnering with a reliable AI development company in USA or an experienced mobile app development company becomes crucial. They bring not just tech chops but also industry know-how that accelerates go-to-market.
<h3 class="wp-block-heading">Final Thoughts</h3>
AI is fundamentally transforming how retail investors engage with stock trading. From automation and insights to mobile-first accessibility and personalized strategies, the barriers are dropping fast.
For fintech founders, portfolio managers, or solo traders—this is the moment to harness AI. And if you're looking to build or scale your next-gen investing solution, choose a tech <a href="https://www.weblineglobal.com/ai-development-company-usa.html">partner </a>who understands both AI and finance.
Because in the markets of tomorrow, intelligent investing starts with intelligent technology.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Fintech news covering the emerging Financial Technology services sector

Fintech

Opinion

How AI Is Transforming Stock Trading For Retail Investors

Barclays analyst Nicholas Campanella maintains Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Overweight and raises the price target from $64 to $65.

Barclays Maintains Overweight on Edison Intl, Raises Price Target to $65

Press Releases

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Comments

Apogee Therapeutics

Apogee Therapeutics (APGE) Opzioni

Apogee Therapeutics (NASDAQ:APGE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO